Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Says USPTO Reverses Rejection of US Patent

Premium

Australia's Benitec said this week that the US Patent and Trademark Office has reversed its previous rejections of claims within the company's core US patent.

The patent, No. 6,573,099, covers gene-expression knockdown using DNA that transcribes double-stranded RNA. It fell under USPTO scrutiny as part of patent-infringement litigation the company initiated against now-defunct expressed RNAi shop Nucleonics, and certain claims within the intellectual property were rejected by the patent office (see GSN, 1/21/2010).

However, Benitec said that the rejection of all appealed claims in the patent has been reversed.

"It is therefore anticipated that the USPTO will soon issue a notice of intent to issue [an] ex parte re-examination certificate … which is analogous to the re-issuance of the patent certificate," the company said. "This notice would formally terminate the re-examination proceeding."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.